September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Changes in Neovascular Activity Following Continuous Anti-Vascular Endothelial Growth Factor Administration in the VIEW Studies
Author Affiliations & Notes
  • Darius M Moshfeghi
    Optometry and Visual Science, Byers Eye Institute at Stanford, Palo Alto, California, United States
  • Footnotes
    Commercial Relationships   Darius Moshfeghi, Regeneron Pharmaceuticals, LLC (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 516. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Darius M Moshfeghi; Changes in Neovascular Activity Following Continuous Anti-Vascular Endothelial Growth Factor Administration in the VIEW Studies
      . Invest. Ophthalmol. Vis. Sci. 2016;57(12):516.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the presence of leakage on fluorescein angiography (FA), the status of retinal fluid on optical coherence tomography (OCT), and the changes in best-corrected visual acuity (BCVA) in the VIEW studies of patients with neovascular age-related macular degeneration (nAMD).

Methods : 2457 nAMD patients were randomized to intravitreal aflibercept injection (IAI) 2 mg q4 weeks (2q4), IAI 0.5 mg q4 weeks (0.5q4), IAI 2 mg q8 weeks after three monthly doses (2q8), or ranibizumab 0.5 mg q4 weeks (Rq4). Independent masked reading centers determined leakage status (no leakage defined as 0 mm2) and fluid status (no fluid defined as the absence of both intraretinal and subretinal fluid) at baseline, week 24 and week 52. Treatment groups were combined and four subgroups were established based on leakage and retinal fluid status: 1) both leakage and fluid present, 2) leakage present, fluid absent, 3) leakage absent, fluid present, 4) both leakage and fluid absent.

Results : At baseline, 95% of patients had both leakage and retinal fluid; 4% of patients had leakage but no fluid; 0.2% of patients had fluid but no leakage; and 0.04% of patients had neither leakage nor retinal fluid. At week 24, the corresponding percentages of patients were 28%, 23%; 14%, and 35% with a mean (standard error) BCVA gain of 7.4 (0.48), 8.6 (0.51), 8.3 (0.79) and 9.9 (0.45) letters, respectively. At week 52, the corresponding percentages of patients were 16%, 19%, 16% and 49% with a mean (standard error) BCVA gain of 9.2 (0.68), 9.6 (0.63), 8.5 (0.88) and 10.3 (0.43) letters, respectively.

Conclusions : The proportion of patients demonstrating absence of both leakage and fluid was 35% at week 24 and 49% at week 52. Gains in BCVA were observed in all subgroups, and appeared dependent on both leakage and retinal fluid status.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×